RALEIGH, NC--(Marketwire - June 28, 2011) -
| Highlighted Links |
|
|
INC Research, LLC, a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, today announced that Chris Smyth, PhD, MBA, has joined its oncology leadership team as senior vice president, Clinical Development. Based out of INC Research’s European headquarters in Winnersh, UK, Dr. Smyth will leverage his extensive oncology expertise to support the company’s oncology development and service delivery efforts in Europe and Asia Pacific.
“We’ve built a strong, global reputation for excellence in oncology by having a dedicated team with the clinical expertise to proactively manage the unique challenges associated with cancer clinical trials,” said Alistair Macdonald, general manager and executive vice president, Oncology at INC Research. “We’re delighted to have someone of Chris’ caliber on board to augment our reputation and capacity to run the highest quality cancer trials and to serve our global customers’ current and future needs.”
Dr. Smyth brings more than 20 years of research and development experience in the pharmaceutical industry, having started his career working in clinical operations roles for CROs. Prior to joining INC Research, he spent eight years at a biopharmaceutical company specializing in the development of small molecules, biologicals and DNA aptamers for the treatment of cancer. He has held senior management positions within CRO and biopharmaceutical companies in both Europe and the US and has been solely focused on hematology and oncology drug development since 2003. Dr. Smyth’s extensive experience and expertise in oncology drug development has successfully ensured the timely and efficient delivery of numerous clinical trials, often ahead of schedule. He received his doctorate in reproductive endocrinology from the University of Edinburgh, UK and his master’s degree in business administration from Henley Management College, UK.
INC Research has conducted more than 350 Phase I through IV oncology trials with nearly 35,000 patients and 4,000 investigative sites around the globe. The team has investigated nearly 130 new and various anticancer therapies, including the introduction of more than 30 new chemical entities (NCEs) in first-in-man trials. The Oncology practice is dedicated to advancing scientific knowledge and helping patients through focused, thoughtful management of critical oncology trials. For more information on INC Research’s Oncology practice, click here. To read its oncology case studies, click here.
About INC Research, LLC
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit www.incresearch.com or follow us at @inc_research.
Media contact:
Kelly Foster
Email Contact
+ 1 619-224-1261
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
